Humana (NYSE:HUM) Upgraded to Overweight at Cantor Fitzgerald

Cantor Fitzgerald upgraded shares of Humana (NYSE:HUM) from a neutral rating to an overweight rating in a research report released on Monday morning, 24/7 WallStreet reports. The firm currently has $345.00 price target on the insurance provider’s stock, up from their previous price target of $300.00.

HUM has been the topic of a number of other research reports. Barclays dropped their price target on Humana from $351.00 to $327.00 and set an overweight rating on the stock in a research note on Wednesday, April 17th. Piper Jaffray Companies increased their price target on Humana from $315.00 to $341.00 and gave the company an overweight rating in a research note on Thursday, August 1st. Morgan Stanley dropped their price target on Humana from $331.00 to $315.00 and set an overweight rating on the stock in a research note on Friday, July 12th. JPMorgan Chase & Co. increased their price target on Humana from $288.00 to $322.00 and gave the company an overweight rating in a research note on Thursday, August 1st. Finally, UBS Group increased their price target on Humana from $266.00 to $317.00 and gave the company a neutral rating in a research note on Thursday, August 1st. One analyst has rated the stock with a sell rating, four have given a hold rating and fifteen have assigned a buy rating to the stock. The stock currently has an average rating of Buy and a consensus price target of $342.26.

Shares of Humana stock opened at $291.06 on Monday. Humana has a 12-month low of $225.65 and a 12-month high of $355.88. The business’s 50 day moving average is $281.32 and its 200-day moving average is $271.43. The company has a quick ratio of 1.75, a current ratio of 1.75 and a debt-to-equity ratio of 0.37. The stock has a market cap of $40.03 billion, a P/E ratio of 20.00, a P/E/G ratio of 1.27 and a beta of 0.85.

Humana (NYSE:HUM) last posted its quarterly earnings results on Wednesday, July 31st. The insurance provider reported $6.05 earnings per share for the quarter, beating analysts’ consensus estimates of $5.24 by $0.81. Humana had a return on equity of 22.47% and a net margin of 4.13%. The business had revenue of $16.25 billion for the quarter, compared to analysts’ expectations of $15.88 billion. During the same quarter in the prior year, the business earned $3.96 EPS. The firm’s revenue for the quarter was up 13.9% on a year-over-year basis. On average, sell-side analysts expect that Humana will post 17.65 EPS for the current year.

A number of hedge funds and other institutional investors have recently modified their holdings of the business. 1ST Source Bank grew its holdings in shares of Humana by 2.8% during the 1st quarter. 1ST Source Bank now owns 1,414 shares of the insurance provider’s stock worth $376,000 after purchasing an additional 39 shares in the last quarter. Cornerstone Advisors Inc. grew its holdings in shares of Humana by 13.5% during the 2nd quarter. Cornerstone Advisors Inc. now owns 353 shares of the insurance provider’s stock worth $94,000 after purchasing an additional 42 shares in the last quarter. Regentatlantic Capital LLC grew its holdings in shares of Humana by 0.4% during the 2nd quarter. Regentatlantic Capital LLC now owns 9,617 shares of the insurance provider’s stock worth $2,551,000 after purchasing an additional 42 shares in the last quarter. Cim Investment Mangement Inc. grew its holdings in shares of Humana by 4.3% during the 2nd quarter. Cim Investment Mangement Inc. now owns 1,125 shares of the insurance provider’s stock worth $298,000 after purchasing an additional 46 shares in the last quarter. Finally, Savant Capital LLC grew its holdings in shares of Humana by 2.5% during the 2nd quarter. Savant Capital LLC now owns 1,968 shares of the insurance provider’s stock worth $522,000 after purchasing an additional 48 shares in the last quarter. 91.33% of the stock is currently owned by hedge funds and other institutional investors.

About Humana

Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. The company offers medical and supplemental benefit plans to individuals. It also has contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.

Further Reading: How to find the components of the quick ratio

Analyst Recommendations for Humana (NYSE:HUM)

Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.